Benzinga · Jul 17, 2026
Bone Biologics Files Prospectus To Offer Up To 6.46M Shares Of Common Stock By Selling Stockholders
https://www.sec.gov/Archives/edgar/data/1419554/000149315226033789/forms-3.htm
NASDAQ · BBLG
Bone Biologics Corporation
Healthcare · Medical - Devices
$0.56
Up+$0.00 (+0.00%)
Updated Sep 9, 2026, 10:47 AM
SID Score
2.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 3.38M
- P/E ratio
- -0.86
- Dividend yield
- 0.00%
- 52-week range
- $0.54 – $2.89
- Volume
- 14.77K
- Avg. volume
- 80.04K
Price performance
BBLG price history
1M range · 0 trading sessions · Daily adjusted prices
BBLG does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest BBLG news
The latest Smart Investors Daily articles mentioning BBLG.
Stock researchCompany · Overview
BBLG research
Overview
Company profile and research snapshot.
Company profile
Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has applications in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 13, 2023 | EF Hutton | Buy | — |
| Apr 3, 2023 | EF Hutton | Buy | — |
| Oct 18, 2022 | EF Hutton | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Mar 3, 2026
Watching Bone Biologics; Zacks Small-Cap Research Gives Stock $22.20/Share Price Valuation
https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_03032026_BBLG_Sorensen.pdf
Yahoo · Jan 8, 2026
Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook
Key accomplishments include expanded rhNELL-1 shelf life, advanced NB1 development, strengthened balance sheet, and maintained Nasdaq complianceBURLINGTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today summarized key corporate, scientific, and operational milestones achieved during 2025 and outlined its strategic outlook for 2026. “We executed wit
defenseworld.net · Dec 11, 2025
Bone Biologics (NASDAQ:BBLG) Shares Down 0.5% – Should You Sell?
Bone Biologics Corp. (NASDAQ: BBLG - Get Free Report)'s share price fell 0.5% during trading on Wednesday. The stock traded as low as $1.9246 and last traded at $2.10. 43,801 shares were traded during trading, an increase of 8% from the average session volume of 40,407 shares. The stock had previously closed at $2.11. Analyst
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
